Roche agreed terms with Hansoh Pharmaceuticals to license an early‑stage antibody‑drug conjugate targeting CDH17 for colorectal cancer, paying an $80 million upfront fee and structuring up to $1.45 billion in milestones. Industry coverage described the transaction as part of a wave of ADC licensing activity, with Hansoh granting Roche global development and commercialization rights. Concurrent industry reports noted additional delivery and licensing deals this week — including a separate Rani Therapeutics agreement with Chugai — underscoring active dealmaking across drug delivery and ADC spaces. Roche characterized the Hansoh asset as a strategic fit to bolster its oncology pipeline and cited preclinical and early clinical signals as the rationale for the investment. For biotech deal teams, the Hansoh‑Roche terms provide a reference point for upfront and milestone structures in ADC collaborations and demonstrate continued large‑cap appetite for early clinical ADC assets.